Genomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and Japan

Mastermind® FLEX Data powers Compass Bioinformatics's InheriNext® platform, bringing unparalleled genomic evidence to leading institutes across US, Japan, and beyond while advancing precision medicine globally

ANN ARBOR, Mich. and TOKYO, Sept. 23, 2025 /PRNewswire/ -- Genomenon, a leading genomic intelligence company, today announced a strategic partnership with Compass Bioinformatics, integrating Genomenon's Mastermind FLEX Data into Compass Bioinformatics' innovative InheriNext platform for genetic disease diagnostics. The Mastermind FLEX data solution is a comprehensive data set that includes expertly curated gene and variant-level content with indexed variant-level information.

This collaboration unites Compass Bioinformatics' AI-powered genomic analysis with data from Genomenon's leading genomic intelligence platform to advance variant interpretation for clinicians and researchers worldwide. It elevates InheriNext for US users and accelerates Mastermind adoption in Japan, while expanding Genomenon's footprint in Asia and establishing its position as the gold standard in genomic evidence.

InheriNext is a rapidly emerging genetic analysis web-based platform and, this year alone, has been deployed in over 40 leading rare disease research and diagnostic institutes in Japan. With more than 10,000 cases analyzed at renowned medical centers, the platform has become a trusted solution for variant analysis and genomic interpretation. By integrating Genomenon's Mastermind FLEX Data, InheriNext users gain insight into the most comprehensive, up-to-date collection of genomic literature in the world, including expertly curated variant data that adheres to ACMG guidelines. This integration boosts clinical confidence by providing comprehensive supporting evidence for pathogenic variant interpretation, reduces time and effort by streamlining manual review processes, and improves patient outcomes by enabling reanalysis of unsolved cases as new knowledge emerges. With Mastermind FLEX Data continuously updated, what was once classified as a VUS (Variant of Uncertain Significance) may now be interpreted with confidence, giving undiagnosed patients new possibilities for answers.

InheriNext delivers automated, accurate, and efficient genomic analysis through domain-specific AI algorithms, phenotype-based ranking, comprehensive data sources, family-based analyses, and integrated reporting tools. The addition of Genomenon's Mastermind FLEX Data strengthens these capabilities by ensuring that every variant interpretation is supported with robust, literature-based evidence.

Frank Ong, CEO, of Compass Bioinformatic explained, "This partnership between Compass Bioinformatics and Genomenon underscores the industry-leading standards and global reach of our respective platforms, enhancing the interpretation of genomic data for our customers, including laboratory directors, researchers, clinicians and patients." 

"We are proud to partner with Genomenon, with Mastermind at the core of this partnership, to bring the very best resources to the clinicians who place their trust in us," stated Ping-Cheng Hsiung, General Manager, Compass Bioinformatics (Japan Subsidiary). "We are confident that our partner clinicians will greatly value the insights that Mastermind delivers!" 

Mike Klein, CEO of Genomenon, said, "Genomenon is thrilled to partner with Compass Bioinformatics to bring Mastermind's gold-standard FLEX Data to InheriNext. This collaboration not only strengthens InheriNext for experienced U.S. users, but also significantly expands our presence in Japan and Asia. Together, we are making a global impact by empowering clinicians with the most comprehensive genomic evidence available."

Interested in exploring InheriNext, now powered with Mastermind, for your institute? Learn more at www.compassbioinfo.com or connect directly with the Compass team at [email protected].

About Compass Bioinformatics

Compass Bioinformatics is a rising star in AI-driven genomic analysis, offering InheriNext®, a software platform that accelerates and improves the diagnosis of genetic diseases. With features including AI-based variant prioritization, private population databases, and a domain-specific LLM chatbot, InheriNext® is trusted by leading research and diagnostic centers worldwide.

Learn more at www.compassbioinfo.com or follow us on LinkedIn. 

About Genomenon

Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world's premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.

Learn more at www.genomenon.com or follow us on LinkedIn.

SOURCE Genomenon